Interaction of antitumor drug Sn(CH3)2Cl2 with DNA and RNA

Mononuclear indolyldithiocarbamates of SnCl4 and R2SnCl2: Spectroscopic, thermal characterizations and cytotoxicity assays in vitro

“…This is in accordance with the findings of Pellerito et al who reports that organotin(IV) complexes exert therapeutic effects on various tumor cells; dialkyltin(IV) complexes being the most effective [42,43]. It has been suggested that these behaviors are exhibited due to the interaction of organotin compounds with DNA at the level of phosphate group, which may be followed by the intercalation of the ligand into DNA [44,45]. Different active organotin compounds may still show slight variations in 'in vitro' cytotoxicity due to different kinetic and mechanistic behavior [46].…”

Design, synthesis, and Gaussia luciferase Assay of triorganotin(IV)-based HCV inhibitors

“…The tin metal ion has an appropriate hard-soft character and abundant valence shell orbital for interaction with oxygen sites (electrovalent bonding) and nitrogen sites of DNA (covalent bonds) (Casas et al, 2004;Li et al, 1996). In case of RNA, binding is mainly through the backbone of phosphate group, but in the presence of high concentration of drug, minor interaction with RNA bases is also observed (Nafisi et al, 2005). The RNA controls the RNA-dependent RNA polymerase NS5B which plays a key role in the life cycle of the virus since it is responsible for the replication of the viral genome (Butcher et al, 2001).…”

Tributyltin(IV)[3‐(3′,5′‐dimethylphenylamido)propanoate] as a potent HCV inhibitor, its delivery study, controlled release and binding sites using CTAB as a standard cell membrane

“…In the quest for exploring effective HCV agent, tributyltin(IV)[3‐(3′,5′‐dimethylphenylamido)propanoate], as shown in Scheme , is synthesized and characterized by different spectroscopic techniques . Organotin(IV) complexes have the ability to bind with RNA and DNA . The extra stability of Sn–RNA adducts over Sn–DNA complexes can be attributed to the lower double helical structure of RNA, which provides greater accessibility to drugs for interaction with RNA bases.…”